Innovent Biologics Inc (SEHK:1801)

APAC company
add to virtual portfolio
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - 1801

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - 1801

  • Market CapHKD0.000m
  • SymbolSEHK:1801
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINKYG4818G1010

Company Profile

Innovent is a China-based biotechnology company that is developing drugs for a wide spectrum of diseases, especially oncology treatments. Founded in 2011, it listed on the Hong Kong Stock Exchange in 2018. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tyvyt or sintilimab. Its other four products are IBI-305, IBI-301, and IBI-303, which are biosimilar versions of bevacizumab, rituximab, and adalimumab. Innovent is partnered with Eli Lilly on Tyvyt and IB-301, as well as several other drugs. Another major strategic partner is Incyte, from whom Innovent has in-licensed three small molecule oncology treatments.

Latest 1801 news

Currently there for this company. Visit our news hub for other news .